ArticleFrontiers in pediatrics2026
Wiskott-Aldrich syndrome: clinical, immunological, and genetic characterization of the first Moroccan cohort.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wiskott-Aldrich syndrome (WAS) is a rare X-linked inborn error of immunity characterized by thrombocytopenia, eczema, and recurrent infections, with additional risks of autoimmunity and malignancy. Country-level data from North Africa are scarce. We report the first genetically confirmed Moroccan series of WAS, describing diagnostic pitfalls, clinical spectrum, and molecular findings. Methods: We conducted a mixed retrospective-prospective observational cohort study of male patients with molecularly confirmed Wiskott-Aldrich syndrome managed at a Moroccan tertiary referral center between January 2017 and September 2024. Clinical features, hematologic and immunologic data, management, and outcomes were collected from hospital records and available follow-up. Results: Ten male patients were included. Thrombocytopenia was present in all patients (100%), followed by recurrent infections in 9/10 patients (90%) and eczema (90%). Autoimmune complications occurred in 2/10 patients (20%), manifesting as systemic lupus erythematosus with lupus-nephritis-compatible disease in one case and autoimmune hemolytic anemia in the other. Mean platelet volume (MPV) was available in 9/10 patients and was reduced in 2/9 (22.2%). Molecular analysis identified seven distinct pathogenic/likely pathogenic variants: two nonsense (p.Gly322* and p.Arg321*), one splice-site (c.735-2A > T), two frameshift (p.Pro330Leufs*115 and p.Arg431Serfs*64), and two missense (p.Val50Asp and p.Phe128Cys). The p.Gly322* variant recurred in three related patients, including twin brothers, while c.735-2A > T was found in two unrelated individuals, highlighting both familial recurrence and allelic heterogeneity. Truncating and splice-site variants predominated in this cohort (8/10, 80%), consistent with previously reported classic WAS cohorts. One child underwent hematopoietic stem cell transplantation (HSCT) abroad with sustained remission, whereas the others remain on supportive therapy with intravenous immunoglobulin and antimicrobial prophylaxis. Conclusions: This first genetically confirmed Moroccan case series expands the clinical and molecular spectrum of Wiskott-Aldrich syndrome in North Africa. Our findings highlight the marked clinical and genetic heterogeneity of WAS and underscore the importance of early molecular diagnosis to guide appropriate management, genetic counseling, and timely referral for curative therapy in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.